Concept Life Sciences confirms Scizys’ compatibility with automated staining – ready for customer sample testing

Lumito AB (publ) announces today that the UK-based contract research organisation Concept Life Sciences has completed the first stage of the evaluation of Lumito's product, Scizys Erbium kit and Scizys scanner. The positive outcome marks a significant step forward in bringing Lumito’s high-sensitivity tissue analysis solution to the market and is strengthening the position of […]

Lumito AB publishes Quarterly Report 2, 2025

Financial overview Second quarter 2025, 1 April to 30 June • Net sales amounted to KSEK 0 (0). • Result after taxes amounted to KSEK -11 275 (-8 132) TSEK. • Basic and diluted earnings per share amounted to SEK -0,04 (-0,04). • Cash flow from operating activities after change in working capital amounted to […]

Further Insights from Scientific Advisory Board Meeting – Confirms the Potential of Lumito’s Innovative Solution for Quantitative Tissue Analysis

At Lumito’s Scientific Advisory Board (SAB) meeting held on June 9, the SAB confirmed the uniqueness and potential of Lumito’s innovative solution, Scizys, for quantitative tissue analysis. Additionally, the advisors were unified in the view that Lumito has a product that will meet the needs of the pharmaceutical industry. The SAB, where a few have […]

Lumito’s Scientific Advisory Board Meeting Held and Additional Key Opinion Leader Joins

Following the establishment of its Scientific Advisory Board (SAB) announced on 5 June 2025, the SAB held a meeting this week, where the uniqueness of Lumito’s solution, Scizys, was confirmed and reaffirmed as a promising technology with the potential to lead the way in quantitative tissue analysis and pathology. Lumito are pleased to announce that […]

Lumito establishes Scientific Advisory Board with leading international experts in drug development, pathology, and oncology

Lumito has established a Scientific Advisory Board (SAB) to primarily support its ongoing commercialisation and, in the longer term, to strengthen the company’s strategic efforts toward a product for clinical use. The board comprises globally recognised experts in pathology, diagnostics, oncology, digitalisation, and drug development, with extensive experience spanning academia, healthcare, and the pharmaceutical industry. […]

Lumito AB publishes Quarterly Report 1, 2025

First quarter 2025, January 1 to March 31 • Net sales amounted to TSEK 0 (17).• Result after taxes amounted to TSEK -11 803 (-7 113).• Earnings per share before and after dilution amounted to SEK -0,04 (-0,03).• Cash flow from operating activities after changes in working capital amounted to TSEK -6 784 (-7,178).• Cash […]

Lumito featured at AACR 2025

The AACR Annual Meeting (American Association for Cancer Research) is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. Lumito gained valuable visibility through a presentation by Professor Paul Waring at Akoya’s Spotlight Theatre, […]

Lumito launches new website – highlighting increasing objectivity in tissue analysis

Lumito, a leading medical technology company focused on tissue analysis, is launching a new website today, centered around the core message: "Increasing objectivity in tissue analysis." "Our new website is a direct result of insights gathered from users and partners," says CEO Sanna Wallenborg. “There has been a clear need to better clarify and deepen […]

Lumito launches new image visualisation and analysis software in partnership with Katana Labs

We are excited to announce that the partnership between Lumito and Katana Labs has resulted in a customised analysis software solution tailored specifically for Lumito’s customers. Lumito and Katana Labs are launching an innovative, cloud-based image analysis and visualisation software. The new solution is specifically optimised for Lumito’s unique Scizys tissue imaging technology, which combines […]